Skip to content

US · INBX · BIOTECHNOLOGY

Inhibrx Biosciences Inc. (INBX) intrinsic value and stock valuation

$68.97as of 2026-11-21 · Mkt cap 1.3B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Inhibrx Biosciences Inc. DCF and intrinsic value

InvestorsCraft values INBX with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from INBX’s statements →

Inhibrx Biosciences Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology La Jolla, CA 92037 inhibrx.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$1.3M-36.7% 5y CAGRd
20162025
Net income
-$-140.06M
20162025
Free cash flow
-$-129.82M
20162025
Total equity
$7.99M-36.2% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$1.3M$200K$1.8M$2.19M$7.12M
Operating income-$-135.03M-$-331.45M-$-219.22M-$-129.12M-$-76.56M
Net income-$-140.06M$1.69B-$-241.36M-$-145.23M-$-81.77M
EPSd-$-9.04M$116.5M-$-5.12M-$-3.62M-$-2.15M
Operating cash flow-$-129.79M-$-194.41M-$-193.31M-$-115.3M-$-80.32M
Capital expenditure-$-30K-$-2.6M-$-4.59M-$-690K-$-860K
Free cash flow-$-129.82M-$-197.01M-$-197.9M-$-115.99M-$-81.19M
Total assets$146.5M$180.8M$307.9M$290.9M$150.5M
Total debt$107M$8.05M$210.1M$207.1M$72.1M
Net debt-$-17.21M-$-144.55M-$-67.78M-$-66.76M-$-59.16M
Total equity$7.99M$133.6M$43.5M$58.1M$52.4M
Cash and short-term investments$124.2M$152.6M$277.9M$273.9M$131.3M
Income statement
20252024202320222021
Revenue$1.3M$200K$1.8M$2.19M$7.12M
Cost of revenue$2.48M$2.29M$1.19M$110.2M$2.69M
Gross profit-$-1.18M-$-2.08M$610K-$-107.99M$4.44M
Research and development expenses$113M$203.7M$190.7M$110.2M$71.4M
Selling, general and administrative expenses$23.3M$127.9M$29.4M$21.1M$12.4M
Other expenses-$-2.48M-$-2.29M-$-200K-$-110.19M-$-71.45M
Operating expenses$133.8M$329.4M$219.8M$21.1M$12.3M
Cost and expenses$136.3M$331.7M$221M$131.3M$83.7M
Interest income$7.55M$10.9M$11.9M$16.1M$5.22M
Interest expense$12.2M$13.5M$31.8M$16.1M$5.22M
Depreciation and amortization$2.48M$2.29M$1.19M$1.23M$1.2M
Ebitda-$-125.37M$1.7B-$-206.69M-$-125.82M-$-75.37M
Operating income-$-135.03M-$-331.45M-$-219.22M-$-129.12M-$-76.56M
Total other income/expenses, net-$-5.03M$2.02B-$-20.5M-$-16.11M-$-5.2M
Income before tax-$-140.05M$1.69B-$-239.72M-$-145.22M-$-81.77M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-140.06M$1.69B-$-241.36M-$-145.23M-$-81.77M
Weighted average shares outstanding$15.5M$14.5M$47.1M$40.1M$38M
Weighted average diluted shares outstanding$15.5M$14.5M$47.1M$40.1M$38M
Balance sheet
20252024202320222021
Cash and short-term investments$124.2M$152.6M$277.9M$273.9M$131.3M
Net receivables$180K$420K$780K$260K$880K
Inventory$0.00$0.00$0.00$0.00-$-880K
Total current assets$132.8M$160.4M$295.4M$280.5M$139.1M
Property, plant and equipment, net$9.27M$13.5M$9.37M$7.22M$9.49M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$13.7M$20.4M$12.5M$10.4M$11.3M
Total assets$146.5M$180.8M$307.9M$290.9M$150.5M
Accounts payable$5.94M$9.24M$11M$8.33M$9.12M
Short-term debt$2.33M$1.59M$2.06M$1.86M$1.67M
Deferred revenue$0.00$0.00$0.00$170K$2.03M
Total current liabilities$33.8M$40.7M$56.3M$27.6M$22.5M
Long-term debt$104.7M$6.45M$208.1M$205.2M$70.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$110K
Total non-current liabilities$104.7M$6.45M$208.1M$205.2M$75.6M
Capital lease obligations$4.13M$6.45M$3.17M$3.17M$0.00
Total liabilities$138.5M$47.2M$264.4M$232.8M$98.1M
Common stock$0.00$0.00$10K$0.00$0.00
Retained earnings-$-246.19M-$-106.13M-$-613.73M-$-372.37M-$-227.15M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00-$-150.45M
Total equity$7.99M$133.6M$43.5M$58.1M$52.4M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$107M$8.05M$210.1M$207.1M$72.1M
Net debt-$-17.21M-$-144.55M-$-67.78M-$-66.76M-$-59.16M
Cash flow statement
20252024202320222021
Net income-$-140.06M$1.69B-$-239.73M-$-145.23M-$-81.77M
Depreciation and amortization$2.48M$2.29M$1.19M$1.23M$1.2M
Stock-based compensation$11.1M$58.5M$24.9M$20.5M$15.1M
Change in working capital-$-7.61M$52.1M$15.4M$3.16M-$-17.52M
Accounts receivable$240K$380K-$-520K$130K-$-170K
Inventory$0.00$0.00$0.00$0.00-$-11.03M
Accounts payable-$-3.3M$17.9M$2.11M-$-700K-$-4.64M
Net cash provided by operating activities-$-129.79M-$-194.41M-$-193.31M-$-115.3M-$-80.32M
Investments in property, plant and equipment-$-30K-$-2.6M-$-4.59M-$-690K-$-860K
Acquisitions, net$0.00$0.00$0.00$0.00$60K
Net cash used for investing activities-$-30K-$-2.6M-$-4.59M-$-690K-$-810K
Common stock issued$1.61M$71.7M$202M$129.7M$40.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$101.5M$71.7M$202M$258.6M$83.8M
Net change in cash-$-28.38M-$-125.33M$4.06M$142.6M$2.64M
Cash at end of period$124.2M$152.6M$277.9M$273.9M$131.3M
Operating cash flow-$-129.79M-$-194.41M-$-193.31M-$-115.3M-$-80.32M
Capital expenditure-$-30K-$-2.6M-$-4.59M-$-690K-$-860K
Free cash flow-$-129.82M-$-197.01M-$-197.9M-$-115.99M-$-81.19M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Inhibrx Biosciences Inc.

        Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

        CEO
        Mark Lappe
        Employees
        110
        Beta
        3.43

        Explore

        Frequently asked questions

        What is the intrinsic value of Inhibrx Biosciences Inc. (INBX)?

        Inhibrx Biosciences Inc. (INBX) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is INBX undervalued?

        INBX trades at a price of $68.97 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.